Skip to main content
. 2023 Nov 27;14:7780. doi: 10.1038/s41467-023-43387-9

Fig. 6. IGF2BP2::TESPA1 fusion breakpoint validation in bulk and scDNA.

Fig. 6

a Genotyping PCR on genomic DNA isolated from matched patient samples using gene-specific primers for IGF2BP2::TESPA1 genomic breakpoint (top), wt TESPA1 (middle) and wt IGF2BP2 (bottom). n = 2 patients, 4 samples per patient, depending on biological material available. Source images are provided as a Source Data file. b Copy number values per subclone in Patient 2 scDNA-seq data. Sublone 0 has multiple copy number alterations, indicative of cancer, while Subclone 1 is copy number neutral, presumably non-cancer. c IGV view of scDNA reads aligning unambiguously to the IGF2BP2::TESPA1 genomic breakpoint (top), wt TESPA1 (middle), or wt IGF2BP2 (bottom). In red, reads from Subclone 0 cells (cancer); in blue, reads from Subclone 1 cells (non-cancer).